Literature DB >> 8801083

Comparative analysis of six European influenza vaccines.

I Chaloupka1, A Schuler, M Marschall, H Meier-Ewert.   

Abstract

Three split-virion vaccines (Vaxigrip, Begrivac, and Influsplit/Fluarix) and three subunit vaccines containing only viral surface glycoproteins (Influvac, Agrippal, and Fluvirin) available for the 1994-95 season were analysed by biological, molecular, and biochemical methods. Although all vaccines are required by health authorities to contain 15 micrograms haemagglutinin per dose of each virus strain, there were significant differences in haemagglutination titres among the examined vaccines of both types. The enzymatic activity of neuraminidase was present in all vaccines except Fluvirin. Total protein content was lower for subunit vaccines. Viral nucleoprotein was detected in all split vaccines but to varying levels according to SDS-PAGE and Western blot analyses. The ovalbumin content was low in general but was about tenfold higher for Influvac than for the other vaccines analysed. This protein may induce hypersensitive reactions among persons with severe egg allergy. All three split-virion vaccines were found to contain the matrix protein; however, it was not detected in the subunit vaccines. Differences in influenza antigen variety in currently available vaccines may affect efficacy, whereas differences in concentrations of nonviral compounds such as ovalbumin and endotoxin may lead to different postvaccination reactogenicity profiles.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8801083     DOI: 10.1007/bf01591484

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates.

Authors:  C R Lambré; H Terzidis; A Greffard; R G Webster
Journal:  J Immunol Methods       Date:  1990-12-31       Impact factor: 2.303

2.  Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene.

Authors:  M A Yankauckas; J E Morrow; S E Parker; A Abai; G H Rhodes; V J Dwarki; S H Gromkowski
Journal:  DNA Cell Biol       Date:  1993-11       Impact factor: 3.311

3.  Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine.

Authors:  G J Gorse; M J Campbell; E E Otto; D C Powers; G W Chambers; F K Newman
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

4.  Licensing and control authority batch release of influenza vaccine in Germany in accordance with EEC regulations.

Authors:  M Weeke-Lüttmann
Journal:  Eur J Epidemiol       Date:  1994-08       Impact factor: 8.082

5.  Recommendations of the 7th European Meeting of Influenza and Its Prevention.

Authors:  M Aymard; N J Cox; G Dubois; Y Ghendon; C Hannoun; A Hampson; L R Haaheim; P Morgan-Capner; P Saliou; S Tamblyn
Journal:  Eur J Epidemiol       Date:  1994-08       Impact factor: 8.082

Review 6.  Influenza: diagnosis, management, and prophylaxis.

Authors:  M Wiselka
Journal:  BMJ       Date:  1994-05-21

7.  Statement on influenza vaccination for the 1994-95 season.

Authors: 
Journal:  CMAJ       Date:  1994-09-01       Impact factor: 8.262

8.  Recommendations for the composition of influenza virus vaccines for the 1994-95 season.

Authors: 
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

9.  Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom.

Authors:  S Renfrey; A Watts
Journal:  Vaccine       Date:  1994-06       Impact factor: 3.641

10.  The B-cell response in lymphoid tissue of mice immunized with various antigenic forms of the influenza virus hemagglutinin.

Authors:  D M Justewicz; P C Doherty; R G Webster
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  13 in total

1.  Ovalbumin content of influenza vaccines.

Authors:  James T Li; Matthew A Rank; Diane L Squillace; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2010-05-07       Impact factor: 10.793

2.  Dose sparing and the lack of a dose-response relationship with an influenza vaccine in adult and elderly patients - a randomized, double-blind clinical trial.

Authors:  Zoltan Vajo; Gergely Balaton; Peter Vajo; Laszlo Kalabay; Adam Erdman; Peter Torzsa
Journal:  Br J Clin Pharmacol       Date:  2017-04-11       Impact factor: 4.335

Review 3.  Current understanding of egg allergy.

Authors:  Jean-Christoph Caubet; Julie Wang
Journal:  Pediatr Clin North Am       Date:  2011-04       Impact factor: 3.278

4.  Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus.

Authors:  Wenwei Tu; Huawei Mao; Jian Zheng; Yinping Liu; Susan S Chiu; Gang Qin; Ping-Lung Chan; Kwok-Tai Lam; Jing Guan; Lijuan Zhang; Yi Guan; Kwok-Yung Yuen; J S Malik Peiris; Yu-Lung Lau
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

5.  Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

Authors:  Benjamin Petsch; Margit Schnee; Annette B Vogel; Elke Lange; Bernd Hoffmann; Daniel Voss; Thomas Schlake; Andreas Thess; Karl-Josef Kallen; Lothar Stitz; Thomas Kramps
Journal:  Nat Biotechnol       Date:  2012-11-25       Impact factor: 54.908

6.  High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza.

Authors:  Kelvin K W To; Anna J X Zhang; Ivan F N Hung; Ting Xu; Whitney C T Ip; Rebecca T Y Wong; Joseph C K Ng; Jasper F W Chan; Kwok-Hung Chan; Kwok-Yung Yuen
Journal:  Clin Vaccine Immunol       Date:  2012-05-09

Review 7.  History of narcolepsy at Stanford University.

Authors:  Emmanuel J M Mignot
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 8.  A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.

Authors:  Karl-Josef Kallen; Regina Heidenreich; Margit Schnee; Benjamin Petsch; Thomas Schlake; Andreas Thess; Patrick Baumhof; Birgit Scheel; Sven D Koch; Mariola Fotin-Mleczek
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

9.  Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes.

Authors:  Theone C Kon; Adrian Onu; Laurentiu Berbecila; Emilia Lupulescu; Alina Ghiorgisor; Gideon F Kersten; Yi-Qing Cui; Jean-Pierre Amorij; Leo Van der Pol
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

10.  The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.

Authors:  Eun Kyeong Kang; Byung Wook Eun; Nam Hee Kim; Jung Sub Lim; Jun Ah Lee; Dong Ho Kim
Journal:  BMC Infect Dis       Date:  2016-08-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.